Dilacor

Di·la·cor

(dĭl′ə-kôr′)
A trademark for the drug diltiazem hydrochloride.
References in periodicals archive ?
diltiazem: Cardizem, Cardizem CD, Cardizem SR, Dilacor XR, Tiazac.
These products, and those under FDA review including Procardia XL and Dilacor XR, will contribute to our future growth.
Watson also seeks damages from Rhone-Poulenc for breach of contract and unfair competition arising, in part, from Rhone-Poulenc 's failure to fulfill its supply obligations to Watson for Dilacor XR branded product and its generic equivalent.
Calcium-Channel Blocking Agents Classification/Drug Trade Names Starting Dosage Amlodipine Norvasc 5 mg QD Diltiazem Cardizem, 30 mg QID or Tiamate, 60-120 mg BID (SR) Cardizem SR, or 180-240 mg QD Cardizem CD, (CD and XR) Dilacor XR, Tiazac Felodipine Plendil 5 mg QD Isradipine DyanaCirc, 2.
Finally, those purporting to look for "conspiracies" ignore the fact that Andrx was the first company to receive FDA approval for a bioequivalent version of Dilacor XR, which we immediately made available to the consumer.
Glucophage(R), OTC generic Claritin-D(R) 24, and Dilacor XR(R), partially offset by increased revenues from our generic versions of Tiazac(R) and Cardizem(R) CD, and Ventolin(R), supplied by Amphastar Pharmaceuticals, Inc.
Especially tell your healthcare provider if you take any of the following medicines : amiodarone (Cordarone, Pacerone), amlodipine (Norvasc), atazanavir (Reyataz), atorvastatin (Lipitor, Caduet), carbamazepine (Carbatrol, Epitol, Equetro, Tegretol), cisapride (Propulsid, Propulsid Quicksolv), clarithromycin (Biaxin, Prevpac), cobicistat-containing medicine: (Stribild), cyclosporine (Gengraf, Neoral, Sandimmune), darunavir (Prezista), delavirdine mesylate (Rescriptor), dexamethasone (when administered by injection or when taken by mouth), digoxin (Lanoxin), diltiazem (Cardizem, Dilacor XR, Tiazac), disopyramide (Norpace), efavirenz (Sustiva, Atripla), erythromycin (E.
Furthermore, the Company announced that it was writing off almost all of its investment in Dilacor XR and that the Company was writing off over $20 million in additional impaired inventory.
Major factors affecting the Company's operating results include net sales of its generic versions of Cardizem CD, and, to a lesser extent, Tiazac, Claritin-D 24, Dilacor XR(R) and Glucophage(R), net sales of its Altocor brand product and KUDCo licensing revenue.
Major factors affecting the Company's operating results include KUDCo licensing revenues and net sales of its generic versions of Cardizem CD, and, to a lesser extent, Tiazac, OTC D-24, Dilacor XR(R) and Glucophage(R) and its brand Altocor product.
Andrx's operating results for the second quarter of 2003 will continue to be highly dependent on KUDCo license revenues, Andrx's ability to manufacture and generate net sales of its generic version of Cardizem CD and, to a lesser extent, its generic versions of Tiazac, Dilacor XR(R) and Glucophage(R), and its brand Altocor product.
Andrx's operating results for the first quarter of 2003 will continue to be highly dependent on KUDCo license revenues, Andrx's ability to manufacture and generate net sales of Altocor, its bioequivalent versions of Cardizem CD and, to a lesser extent, Dilacor XR(R) and Glucophage, and whether Andrx launches significant additional bioequivalent products.